JP2015534991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534991A5 JP2015534991A5 JP2015538226A JP2015538226A JP2015534991A5 JP 2015534991 A5 JP2015534991 A5 JP 2015534991A5 JP 2015538226 A JP2015538226 A JP 2015538226A JP 2015538226 A JP2015538226 A JP 2015538226A JP 2015534991 A5 JP2015534991 A5 JP 2015534991A5
- Authority
- JP
- Japan
- Prior art keywords
- thiopyrano
- tetrahydro
- fluoro
- methylamino
- diol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 125000003342 alkenyl group Chemical group 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000000304 alkynyl group Chemical group 0.000 claims description 48
- 229910052731 fluorine Inorganic materials 0.000 claims description 48
- 125000001153 fluoro group Chemical group F* 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 18
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000034799 Tauopathies Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 125000006308 propyl amino group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- MWNSLTYIIVHOQL-BZCSJUTBSA-N (3ar,5r,6s,7ar)-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H]([C@H](C)O)S[C@@H]2SC(NC)=N[C@@H]21 MWNSLTYIIVHOQL-BZCSJUTBSA-N 0.000 claims description 2
- MLLXFDVHCCYLQB-JGKVKWKGSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-(prop-2-ynylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)S[C@@H]2SC(NCC#C)=N[C@@H]21 MLLXFDVHCCYLQB-JGKVKWKGSA-N 0.000 claims description 2
- JVQQLIJJIHETCG-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-[methoxy(methyl)amino]-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H](CO)S2)O)[C@H]2SC(N(C)OC)=N1 JVQQLIJJIHETCG-FMDGEEDCSA-N 0.000 claims description 2
- NKWWAKGWZXYHJT-JMHNFOGYSA-N (3ar,5r,6s,7r,7ar)-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@H](C)O)S2)O)[C@H]2SC(NC)=N1 NKWWAKGWZXYHJT-JMHNFOGYSA-N 0.000 claims description 2
- VTMABFSHBNXTCW-HDLKOFKZSA-N (3ar,5r,6s,7r,7ar)-5-[(s)-hydroxy(phenyl)methyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound C1([C@H](O)[C@H]2S[C@H]3[C@@H]([C@H]([C@@H]2O)O)N=C(S3)NC)=CC=CC=C1 VTMABFSHBNXTCW-HDLKOFKZSA-N 0.000 claims description 2
- REQZJMOBRFKGGT-ZNSALQAWSA-N (3ar,5r,6s,7r,7ar)-5-[(s)-hydroxy(pyridin-3-yl)methyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound C1([C@H](O)[C@H]2S[C@H]3[C@@H]([C@H]([C@@H]2O)O)N=C(S3)NC)=CC=CN=C1 REQZJMOBRFKGGT-ZNSALQAWSA-N 0.000 claims description 2
- ORWXWXFTGYXWLY-JMHNFOGYSA-N (3ar,5r,6s,7r,7ar)-7-fluoro-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@H](C)O)S2)F)[C@H]2SC(NC)=N1 ORWXWXFTGYXWLY-JMHNFOGYSA-N 0.000 claims description 2
- ULQATFNIZULGRZ-UELCQGJWSA-N (3ar,5s,6s,7ar)-5-(difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound C1[C@H](O)[C@@H](C(F)F)S[C@@H]2SC(NC)=N[C@@H]21 ULQATFNIZULGRZ-UELCQGJWSA-N 0.000 claims description 2
- IHMSPWGRROGUCB-NTXXKDEISA-N (3ar,5s,6s,7r,7ar)-2-(azetidin-1-yl)-7-fluoro-5-[(1s)-2,2,2-trifluoro-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound S([C@H]1S[C@@H]([C@H]([C@H](F)[C@H]1N=1)O)[C@@H](O)C(F)(F)F)C=1N1CCC1 IHMSPWGRROGUCB-NTXXKDEISA-N 0.000 claims description 2
- OJJTZSAZGYIMDH-FJPOHGBRSA-N (3ar,5s,6s,7r,7ar)-2-(methylamino)-5-[(1s)-2,2,2-trifluoro-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@@H](O)C(F)(F)F)S2)O)[C@H]2SC(NC)=N1 OJJTZSAZGYIMDH-FJPOHGBRSA-N 0.000 claims description 2
- BTTYPUZBBMQPNX-RLZVPWTLSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H](C(F)F)S2)F)[C@H]2SC(NC)=N1 BTTYPUZBBMQPNX-RLZVPWTLSA-N 0.000 claims description 2
- UAURVGMIFJYDPD-NYMZXIIRSA-N (3ar,5s,6s,7r,7ar)-7-fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H](CF)S2)F)[C@H]2SC(NC)=N1 UAURVGMIFJYDPD-NYMZXIIRSA-N 0.000 claims description 2
- BTTYPUZBBMQPNX-SDDMPLOYSA-N (3ar,5s,6s,7s,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]thiazol-6-ol Chemical compound [C@@H]1([C@@H]([C@H](O)[C@@H](C(F)F)S2)F)[C@H]2SC(NC)=N1 BTTYPUZBBMQPNX-SDDMPLOYSA-N 0.000 claims description 2
- OFHDLQIPFPSNRW-YMVPXFTJSA-N (3as,5r,6s,7ar)-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound C1[C@H](O)[C@@H]([C@H](C)O)S[C@@H]2OC(NC)=N[C@@H]21 OFHDLQIPFPSNRW-YMVPXFTJSA-N 0.000 claims description 2
- GNRIQRPBAHFTHH-MZNFZHPNSA-N (3as,5r,6s,7r,7ar)-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazole-6,7-diol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@H](C)O)S2)O)[C@H]2OC(NC)=N1 GNRIQRPBAHFTHH-MZNFZHPNSA-N 0.000 claims description 2
- SPFWTDOICVQDMX-MZNFZHPNSA-N (3as,5r,6s,7r,7ar)-7-fluoro-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@H](C)O)S2)F)[C@H]2OC(NC)=N1 SPFWTDOICVQDMX-MZNFZHPNSA-N 0.000 claims description 2
- SPFWTDOICVQDMX-RJDKYLDESA-N (3as,5r,6s,7s,7ar)-7-fluoro-5-[(1s)-1-hydroxyethyl]-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound [C@@H]1([C@@H]([C@H](O)[C@@H]([C@H](C)O)S2)F)[C@H]2OC(NC)=N1 SPFWTDOICVQDMX-RJDKYLDESA-N 0.000 claims description 2
- JTKJZPKDGCQYNZ-GZFNIDBVSA-N (3as,5s,6s,7ar)-5-(difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound C1[C@H](O)[C@@H](C(F)F)S[C@@H]2OC(NC)=N[C@@H]21 JTKJZPKDGCQYNZ-GZFNIDBVSA-N 0.000 claims description 2
- DYDCDUIFQMZNEJ-JIOKVTTDSA-N (3as,5s,6s,7r,7ar)-2-(methylamino)-5-[(1s)-2,2,2-trifluoro-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazole-6,7-diol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H]([C@@H](O)C(F)(F)F)S2)O)[C@H]2OC(NC)=N1 DYDCDUIFQMZNEJ-JIOKVTTDSA-N 0.000 claims description 2
- GCPIGPCFFXDKST-NRGGUMNKSA-N (3as,5s,6s,7r,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H](C(F)F)S2)F)[C@H]2OC(NC)=N1 GCPIGPCFFXDKST-NRGGUMNKSA-N 0.000 claims description 2
- XTOHHFAZZIZQDF-GKHCUFPYSA-N (3as,5s,6s,7r,7ar)-7-fluoro-5-(fluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound [C@@H]1([C@H]([C@H](O)[C@@H](CF)S2)F)[C@H]2OC(NC)=N1 XTOHHFAZZIZQDF-GKHCUFPYSA-N 0.000 claims description 2
- GCPIGPCFFXDKST-RUPLCCJZSA-N (3as,5s,6s,7s,7ar)-5-(difluoromethyl)-7-fluoro-2-(methylamino)-5,6,7,7a-tetrahydro-3ah-thiopyrano[3,2-d][1,3]oxazol-6-ol Chemical compound [C@@H]1([C@@H]([C@H](O)[C@@H](C(F)F)S2)F)[C@H]2OC(NC)=N1 GCPIGPCFFXDKST-RUPLCCJZSA-N 0.000 claims description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 claims description 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims description 2
- 206010058284 Allergy to arthropod sting Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000004434 Calcinosis Diseases 0.000 claims description 2
- 208000020446 Cardiac disease Diseases 0.000 claims description 2
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018341 Gliosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 206010024715 Liver transplant rejection Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010051604 Lung transplant rejection Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000002308 calcification Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 201000005311 drug allergy Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 230000007387 gliosis Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 2
- 230000004112 neuroprotection Effects 0.000 claims description 2
- 210000004940 nucleus Anatomy 0.000 claims description 2
- 210000004738 parenchymal cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 0 C[C@@]1(*)[C@](C)(*)[C@@](C(*)(*)*)N[C@@](*2)[C@@]1*=C2*(*)* Chemical compound C[C@@]1(*)[C@](C)(*)[C@@](C(*)(*)*)N[C@@](*2)[C@@]1*=C2*(*)* 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- -1 salt compound Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720708P | 2012-10-31 | 2012-10-31 | |
| US61/720,708 | 2012-10-31 | ||
| PCT/CA2013/050822 WO2014067003A1 (en) | 2012-10-31 | 2013-10-30 | Glycosidase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018117768A Division JP2018172405A (ja) | 2012-10-31 | 2018-06-21 | グリコシダーゼ阻害剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015534991A JP2015534991A (ja) | 2015-12-07 |
| JP2015534991A5 true JP2015534991A5 (https=) | 2016-11-24 |
Family
ID=50626257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538226A Pending JP2015534991A (ja) | 2012-10-31 | 2013-10-30 | グリコシダーゼ阻害剤およびその使用 |
| JP2018117768A Pending JP2018172405A (ja) | 2012-10-31 | 2018-06-21 | グリコシダーゼ阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018117768A Pending JP2018172405A (ja) | 2012-10-31 | 2018-06-21 | グリコシダーゼ阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9695197B2 (https=) |
| EP (1) | EP2914604A4 (https=) |
| JP (2) | JP2015534991A (https=) |
| KR (1) | KR20150079711A (https=) |
| CN (1) | CN104837845B (https=) |
| AU (1) | AU2013337570B2 (https=) |
| BR (1) | BR112015009638A2 (https=) |
| CA (1) | CA2890115A1 (https=) |
| RU (1) | RU2672873C2 (https=) |
| WO (1) | WO2014067003A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2321289A4 (en) | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013033098B8 (pt) | 2011-06-27 | 2021-03-23 | Alectos Therapeutics Inc | inibidores de glicosidade seletivos e usos dos mesmos |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| PE20211591A1 (es) | 2018-09-19 | 2021-08-18 | Biogen Ma Inc | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
| WO2020229968A1 (en) * | 2019-05-10 | 2020-11-19 | Alectos Therapeutics Inc. | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS423500Y1 (https=) | 1964-02-29 | 1967-03-01 | ||
| DE2632243C3 (de) | 1976-07-17 | 1979-08-30 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen |
| SU703531A1 (ru) * | 1977-09-02 | 1979-12-15 | Институт Химии Нефти И Природных Солей Ан Казахской Сср | Способ получени изоксазолинов, конденсированных с гетероциклическими соединени ми |
| DE3620645A1 (de) | 1985-12-20 | 1987-07-02 | Bayer Ag | 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung |
| JPS6461459A (en) | 1987-08-28 | 1989-03-08 | Nippon Shinyaku Co Ltd | Moranoline derivative |
| JPH01180894A (ja) | 1988-01-07 | 1989-07-18 | Wako Pure Chem Ind Ltd | アミノ糖誘導体の新規な製造法 |
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| US5079254A (en) | 1990-06-04 | 1992-01-07 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 6-aminooctahydroindolizinetriol |
| WO1992003415A1 (en) | 1990-08-14 | 1992-03-05 | Nova Pharmaceutical Corporation | Protein kinase c modulators |
| US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
| US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US5451679A (en) | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
| JPH07316178A (ja) | 1994-05-25 | 1995-12-05 | Sankyo Co Ltd | 糖アミノオキサゾリン類 |
| CN1131672A (zh) | 1994-11-22 | 1996-09-25 | 生化学工业株式会社 | 氨基环戊烷衍生物 |
| AU724003B2 (en) | 1995-09-08 | 2000-09-07 | Novo Nordisk A/S | 2-alkylpyrrolidines |
| CA2235415A1 (en) | 1995-09-08 | 1997-03-13 | Novo Nordisk A/S | 2-alkylpyrrolidines |
| JPH09132585A (ja) | 1995-11-10 | 1997-05-20 | Shin Etsu Chem Co Ltd | 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法 |
| US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
| JPH11349541A (ja) | 1998-06-08 | 1999-12-21 | Sankyo Co Ltd | アロサミゾリン誘導体の新規な中間体 |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6774140B1 (en) | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| DE60045217D1 (de) | 1999-05-11 | 2010-12-23 | Scripps Research Inst | Iminocyclitol-inhibitoren von hexoaminidase und glycosidase |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| JP4233262B2 (ja) | 2001-03-14 | 2009-03-04 | 生化学工業株式会社 | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 |
| US7105320B2 (en) | 2001-03-14 | 2006-09-12 | Denki Kagaku Kogyo Kabushiki Kaisha | Process for producing hyaluronic acid or its derivative |
| WO2003008379A1 (en) | 2001-06-08 | 2003-01-30 | Mitsubishi Chemical Corporation | Azasugar compounds |
| JP4866515B2 (ja) | 2001-07-02 | 2012-02-01 | 生化学工業株式会社 | 糖オキサゾリン誘導体の製造方法 |
| BR0211468A (pt) | 2001-07-24 | 2004-11-23 | Univ Yale | Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero |
| US20070066543A1 (en) | 2003-05-22 | 2007-03-22 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| CN1548053A (zh) | 2003-05-23 | 2004-11-24 | 华晶基因技术有限公司 | 黄芩甙作为治疗焦虑症的药物的新用途 |
| AU2004272345A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005072268A2 (en) | 2004-01-20 | 2005-08-11 | Optimer Pharmaceuticals, Inc. | Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors |
| WO2006016904A2 (en) | 2004-04-14 | 2006-02-16 | Uab Research Foundation | Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| US20080096932A1 (en) | 2004-07-23 | 2008-04-24 | Darren Mansfield | 3-Pyridinylethylcarboxamide Derivatives as Fungicides |
| JP4023500B2 (ja) | 2004-08-03 | 2007-12-19 | ソニー株式会社 | イヤホンアンテナ |
| EP1789413A1 (en) | 2004-09-13 | 2007-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7884115B2 (en) | 2004-09-28 | 2011-02-08 | Allergan, Inc. | Methods and compositions for the treatment of pain and other neurological conditions |
| CA2599843C (en) | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
| TW200800220A (en) | 2005-10-26 | 2008-01-01 | Boehringer Ingelheim Int | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
| US7919521B2 (en) | 2005-12-05 | 2011-04-05 | Academia Sinica | Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics |
| AU2007291870B2 (en) | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CN107253970A (zh) * | 2006-08-31 | 2017-10-17 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2321289A4 (en) | 2008-08-01 | 2011-11-16 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE |
| WO2010015815A2 (en) | 2008-08-05 | 2010-02-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| EP2323652A2 (en) | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| CA2737267A1 (en) | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| AT507745B1 (de) | 2008-12-16 | 2012-01-15 | Forschungsholding Tu Graz Gmbh | Fluorophile glykosidasehemmer |
| WO2011060397A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
| EP2566876A4 (en) * | 2010-05-06 | 2014-01-08 | Univ Fraser Simon | METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES |
| WO2011140640A1 (en) * | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) * | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| WO2012061971A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) * | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| WO2012127506A1 (en) | 2011-03-22 | 2012-09-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013033098B8 (pt) | 2011-06-27 | 2021-03-23 | Alectos Therapeutics Inc | inibidores de glicosidade seletivos e usos dos mesmos |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9126957B2 (en) | 2011-08-18 | 2015-09-08 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| ES2568603T3 (es) | 2011-08-25 | 2016-05-03 | Merck Patent Gmbh | Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasas |
| EP2847199B1 (en) | 2012-05-08 | 2017-10-25 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| US9522883B2 (en) | 2012-08-31 | 2016-12-20 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890679A4 (en) | 2012-08-31 | 2016-05-04 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-30 KR KR1020157013109A patent/KR20150079711A/ko not_active Ceased
- 2013-10-30 RU RU2015120556A patent/RU2672873C2/ru not_active IP Right Cessation
- 2013-10-30 JP JP2015538226A patent/JP2015534991A/ja active Pending
- 2013-10-30 AU AU2013337570A patent/AU2013337570B2/en not_active Ceased
- 2013-10-30 WO PCT/CA2013/050822 patent/WO2014067003A1/en not_active Ceased
- 2013-10-30 CN CN201380064854.XA patent/CN104837845B/zh not_active Expired - Fee Related
- 2013-10-30 BR BR112015009638A patent/BR112015009638A2/pt not_active Application Discontinuation
- 2013-10-30 EP EP13852129.9A patent/EP2914604A4/en not_active Ceased
- 2013-10-30 CA CA2890115A patent/CA2890115A1/en not_active Abandoned
- 2013-10-30 US US14/439,790 patent/US9695197B2/en not_active Expired - Fee Related
-
2018
- 2018-06-21 JP JP2018117768A patent/JP2018172405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534991A5 (https=) | ||
| JP2014501740A5 (https=) | ||
| JP2014524911A5 (https=) | ||
| JP2012502884A5 (https=) | ||
| JP2013541596A5 (https=) | ||
| JP2010501598A5 (https=) | ||
| RU2015120556A (ru) | Ингибиторы гликозидаз и их применения | |
| RU2013134345A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| RU2014102232A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| Zhi et al. | Hybrid antibacterials. DNA polymerase− topoisomerase inhibitors | |
| JP2011529858A5 (https=) | ||
| KR101655635B1 (ko) | 피리미딘 pde10 억제제 | |
| JP6740354B2 (ja) | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 | |
| JP2011529857A5 (https=) | ||
| WO2008025170B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| TW201831464A (zh) | 作為激酶抑制劑之雜環醯胺 | |
| JP2014527060A5 (https=) | ||
| MX2026001143A (es) | Compuestos y metodos dirigidos a la tau humana | |
| JP5995975B2 (ja) | Ｍｔｏｒ阻害剤としてのモルホリノ置換尿素またはカルバメート誘導体 | |
| JP2014531449A (ja) | キナーゼ阻害剤としてのピラゾロ［４，３―ｃ］ピリジン誘導体 | |
| WO2007079982A1 (de) | (2 , 4 , 9-triaza-1 (2 , 4 ) -pyrimidina-3 ( 1 , 3 ) -benzenacyclononaphan-3 4-yl) -sulfoximin derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs | |
| JP2015503609A5 (https=) | ||
| RU2013126531A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP2020527173A5 (https=) | ||
| TWI377204B (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |